Trastuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Trastuzumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
1251
Registered trials
1230
Result records
194
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Trastuzumab can convert its Monoclonal antibody profile and HER2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Trastuzumab (query alias: trastuzumab) |
|---|---|
| Modality / target | Monoclonal antibody; HER2; HER2 antagonists, ADCC |
| Highest global status | Approved |
| Originator | Genentech, Inc. |
| Active developers | F. Hoffmann-La Roche Ltd., Roche Registration GmbH, Genentech, Inc. |
The MCP disease footprint includes HER2 Positive Colorectal Cancer, HER2 positive salivary gland cancer, HER2-positive gastric cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| No matched detailed trial record returned. | ||||
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, <i>ERBB2</i> -Positive Breast Cancer
Phase 2; n=98; evaluation: Positive. Reported fields: EFS(5-year) = 99.0 % ( 97 - 100)
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
Phase 3; n=766; evaluation: Positive. Reported fields: pCR = 64.1 % ( 59.1 - 69.0); pCR = 65.9 % ( 60.9 - 70.6)
Prospective analysis of cardiovascular complications in HER2-positive breast cancer patients treated with anthracycline-free regimens.
Not Applicable; n=188; evaluation: Positive. Reported fields: CTRTD = Risk stratification by the HFA-ICOS scale showed no statistically significant prognostic value for overall CVC: frequency was 39% in the high/very high-risk group vs 26% in the low/moderate-risk group (p = 0.169). However, for the specific endpoint of cancer therapy-related cardiac dysfunction (CTRTD), the HFA-ICOS scale showed a statistically significant but clinically modest association (OR = 2.39, 95% CI 1.002-5.70, p = 0.045).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Trastuzumab addresses HER2 Positive Colorectal Cancer, HER2 positive salivary gland cancer, HER2-positive gastric cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 194 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HER2 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-14 | Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy | Approved | US$600.0M upfront; US$900.0M milestones |
| 2026-07-06 | Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis | Preclinical | US$1,100.0M upfront; US$1,500.0M stated total |
| 2026-06-09 | GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year | NDA/BLA | US$8,524.4M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination of Anti-her2 antibody-drug conjugate and her dimerization inhibitor for treatment of solid tumor”. The milestone feed surfaced a patent-application signal described as “Combination therapies for treatment of her2 cancer”. The milestone feed surfaced a patent-application signal described as “Trastuzumab-modified AIE fluorescent nanoparticles as well as preparation method and application thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
